Medical News
Addiction
Allergies
Alternative Medicine
Asthma
Cancer
Cardiology
Chiropractic
Dental
Dermatology
Diabetes
Emergency
Family Medicine
General
Geriatrics
Hospitals
Infectious Diseases
Internal Medicine
Managed Care / HMO
Medical Products
Mental Health
Neurology
Nursing
Nutrition
OB / GYN
Pediatrics
Pharmaceuticals
Physical Therapy
Plastic Surgery
Psychology
Radiology / Imaging
Research
Sports Medicine
Surgery
Vision

Indonesia Reports Experiencing Human H5N1 Mortality Increase, as Predicted Last Year by Replikins' FluForecast® Quantitative Virus Analysis

Recent interviews with Indonesian health officials indicate that two key predictions made in 2006 by Replikins' proprietary epidemic forecasting software were correct - that a strain of H5N1 Bird Flu with increased virulence would emerge in 2007, and that it would emerge in Indonesia. The company plans to parlay this success into further contracts with governments and corporate vaccine groups.

Boston, MA (PRWEB) June 8, 2007 -- The results published in 2006 by Replikins, Ltd. showed that 2005-2006 FluForecast® virus data indicated clearly that 1) the mortality rate of human H5N1 was increasing markedly, and that 2) the first country in which this would be clinically realized would be Indonesia.

Two days ago, Bayu Krisnamurthi, the head of Indonesia's avian flu control commission, reported the clinical realization of both of these two predictions (Canadian Press, June 6, 2007). In his comments to reporters, Dr. Krisnamurthi stated that recent changes in the H5N1 virus seem to be increasing its rate and ease of transmission from birds to humans.

The World Health Organization (WHO), which has not yet used the FluForecast® Service, has reported that as yet they had no evidence of these changes. FluForecast, an automated software-based system for pinpointing genomic changes in viruses, is the only system which has successfully predicted, well in advance, each outbreak of H5N1 bird flu over the past seven years. Recent discovery of the Replikin Peak Gene and improvements in its Replikins' patented technology have allowed prediction of the geographic location, as well as the gene location and the host animal species of each outbreak. The announcement by Dr. Krisnamurthi represents the first independent government confirmation of the success of these improved capabilities.

This new Replikins, Ltd. service is now being applied to other viruses and other infectious organisms. The company's services are available both to government organizations and pharmaceutical companies.

Contact:
John McKenney
Replikins, LLC.
Boston, MA
tel: 617-536-0220

###

Simillar Articles

H5N1 Virus Replikin Gene Counts Indicate a New More Virulent Influenza Cycle Has Begun
Replikins Ltd. has found that H5N1 virus replikin peak gene counts in 2007 in Hong Kong, Russia, Indonesia, Vietnam and Israel indicate that a new replikin cycle has begun. The mean replikin count...
H1N1 Influenza Virus with Highest Replikin CountTM Since the 1918 Pandemic Identified in the U.S....
Replikins, Ltd. has found that the Replikin Count™ of the H1N1 strain of influenza virus has recently increased to 7.6 (plus/minus 1.4), its highest level since the 1918 H1N1 pandemic (p...
FluForecast® Replikin Count™ Predicts That The H5N1 Cycle Which Began In 1996 is Now...
Replikins Ltd. announced that the quantitative analysis of Replikin CountTM in the virus gene structure predicts that the current H5N1 cycle is over. Sporadic outbreaks may continue, but the rapid...
Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
Replikins, Ltd. today announced its latest findings regarding the virus replikin count in human H5N1 influenza virus. The company's software-driven analysis has found that the prevalence of...
Respirators Recommended by Leading Health Organizations Inadequate to Protect Users from H5N1...
The Centers for Disease Control, World Health Organization and National Institute for Occupational Safety and Health all recommend the use of N95 respirators that are unlikely to be effective at...
Home Terms of Use Privacy Policy Contact Us